ARCHIVES

Rescission Cuts $5-6 Mil. From NCI FY94 Appropriations , Affects Intramural Program

This article is from The Cancer Letter archive.

Vol. 20 No. 10 | March 11, 1994

Download PDF Visit The Full Archive

Related Articles

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014

FDA, CMS Take Second Look at Drugs Given “Accelerated” Approval for Cancer

February 21, 2003

ODAC Finds Increase In Progression-Free Survival Unconvincing To Approve sNDA For Gemzar In Advanced Ovarian Cancer.

March 24, 2006

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

Trials Approved by NCI CTEP For the Month of April

April 27, 2012

In Brief: BMS Chemistry Awards to Honor Fu, Wood; Groshow Joins NCI; Bowman Moves to TJU

January 15, 1999